Physician profile
Jonathan Michael Angotti
NPI 1487033387
$2,264.48
in general payments reported to CMS, 2019-2025
22 companies · $22.23 in 2025
The $22.23 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $879 · 2021: $346 · 2022: $950 · 2023: $51.50 · 2024: $15.56 · 2025: $22.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $89.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $89.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Veran Medical Technologies, INC. | $758.80 | 2019 | |
| Glaxosmithkline, LLC. | $277.75 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $188.37 | 2019-2022 | |
| Genentech USA, INC. | $126.04 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.13 | 2021-2022 | |
| Grifols USA, LLC | $110.03 | 2021-2022 | |
| Insmed, INC. | $98.87 | 2021-2022 | |
| Baxter Healthcare | $80.28 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $70.27 | 2022-2023 | Dupixent |
| United Therapeutics Corporation | $67.12 | 2022 | |
| Genzyme Corporation | $65.42 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $60.83 | 2021-2023 | Glassia |
| Inogen, INC. | $36.73 | 2022 | |
| Mylan Specialty L.P. | $34.73 | 2022 | |
| Electromed, INC. | $34.06 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Advanced Respiratory, INC | $32.61 | 2021 | |
| Abbvie INC. | $29.78 | 2022-2024 | |
| Pfizer INC. | $20.33 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $17.61 | 2022 | |
| Nabriva Therapeutics, Plc | $17.43 | 2022 | |
| Mallinckrodt Hospital Products INC. | $15.32 | 2022 | |
| Merck Sharp & Dohme LLC | $11.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Angotti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.